Complete Deficiency of Plasminogen-Activator Inhibitor Type 1 Due to a Frame-Shift Mutation.
Fay, William P. M.D.; Shapiro, Amy D. M.D.; Shih, Judy L.; Schleef, Raymond R. Ph.D.; Ginsburg, David M.D.
[Article] New England Journal of Medicine. 327(24):1729-1733, December 10, 1992.

(Format: HTML, PDF)

: THE process of plasminogen activation is considered a critical component of diverse biologic systems in humans. This reaction, which is catalyzed in vivo by tissue-type and urokinase-type plasminogen activators, results in the conversion of plasminogen to plasmin. Plasmin has an essential role in maintaining vascular patency by converting fibrin to soluble fibrin-degradation products. In addition, plasminogen activators have been implicated in the regulation of embryogenesis, angiogenesis, ovulation, inflammation, and tumor metastasis,1 suggesting that the plasminogen-activation system is an important mediator of tissue remodeling and cell migration.

The activity of plasminogen activators is precisely regulated by several mechanisms.1 Critical among these [horizontal ellipsis]

Owned, published, and (C) copyrighted, 1992, by the MASSACHUSETTS MEDICAL SOCIETY